| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
NSC-95397 is a novel, potent, and selective CDC25B inhibitor which inhibits influenza A virus replication in dose-dependent fashion. NSC 95397 also inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway.NSC95397 prevents the CtBP1-Protein Partner Interaction and CtBP1-Mediated Transcriptional Repression. NSC-95397 triggers apoptosis of tumor cells and is thus considered for the treatment of malignancy. NSC 95397 is a Cdc25 dual specificity phosphatase inhibitor (Ki=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC50=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B)).
| ln Vitro |
In a concentration-dependent way, NSC 95397 (0, 10, and 20 μM; 24 h) decreases the cell survival of clear ducts SW480, SW620, and DLD-1 [2]. Within 24 hours, NSC 95397 (10 μM) folds CDK4 and CDK6, upregulates p21, and affects all bladder waveform line SW480, SW620, and DLD-1 cells [2]. At 10 μM, NSC 95397 decreases the amount of collagenoblast tumor protein on Ser795 and Ser807/811; at 20 μM, NSC 95397 dramatically raises the amounts of internal caspase-9, -3, -7, and PARP [2]. After 6 hours at 10 μM, NSC 95397 improved its downstream.
|
|---|---|
| Cell Assay |
Cell viability assay [2]
Cell Types: human colon cancer cell line, SW480, SW620 and DLD-1 Tested Concentrations: 0, 10 and 20 μM Incubation times ERK1/ Phosphorylation of 2 at Thr202/Tyr 204[2]. Incubation Duration: 24 hour Experimental Results: IC50 values of NSC 95397 for SW480, SW620 and DLD-1 cell growth were 9.9, 14.1 and 18.6 μM respectively. Western Blot Analysis[2] Cells Lines: SW480, SW620 and DLD-1 Cell Tested Concentrations: 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: Upregulation of p21, downregulation of CDK4 and CDK6. diminished phosphorylation of Rb on Ser795 and Ser807/811 |
| References |
[1]. Lazo JS, et al. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol. 2002 Apr;61(4):720-8.
[2]. Dubey NK, et al. NSC 95397 Suppresses Proliferation and Induces Apoptosis in Colon Cancer Cells through MKP-1 and the ERK1/2 Pathway. Int J Mol Sci. 2018 May 31;19(6). pii: E1625. |
| Molecular Formula |
C14H14O4S2
|
|---|---|
| Molecular Weight |
310.38856
|
| CAS # |
93718-83-3
|
| SMILES |
O=C1C(SCCO)=C(SCCO)C(C2=C1C=CC=C2)=O
|
| InChi Key |
MAASHDQFQDDECQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H14O4S2/c15-5-7-19-13-11(17)9-3-1-2-4-10(9)12(18)14(13)20-8-6-16/h1-4,15-16H,5-8H2
|
| Chemical Name |
2,3-Bis(2-hydroxyethylsulfanyl)naphthalene-1,4-dione
|
| Synonyms |
NSC-95397; NSC95397; NSC 95397
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~322.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 10 mg/mL (32.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 10 mg/mL (32.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2218 mL | 16.1088 mL | 32.2175 mL | |
| 5 mM | 0.6444 mL | 3.2218 mL | 6.4435 mL | |
| 10 mM | 0.3222 mL | 1.6109 mL | 3.2218 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA